In trials, Revolution Medicines' daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.
Daraxonrasib is taken daily by mouth. Instead of binding to KRAS directly, it attaches to a molecule called cyclophilin A in cells that helps fold proteins into their final 3D structures. This protein ...
The Food and Drug Administration (FDA) cleared the once-daily tablet, Rasonque, for certain adults with metastatic pancreatic ...
The agency’s officials announced it gave the pill daraxonrasib approval more than six months ahead of a target date.
The federal rules about the drug-fighting drug seemed to carry a message that some patients can be trusted; others, not so ...
A Richmond County judge has vacated the murder conviction and life sentence of a mother found guilty in the 2014 death of her ...
Dolly Parton’s death is bringing new attention to her history of recurring kidney stones. A Duke Health urologist explains ...
Two Frankfurt airport workers have died after contracting malaria from a mosquito believed to have hitched a ride on an ...
The Owosso Fire Department has purchased a new ambulance that will help first responders continue to provide high-quality ...
The Department of Health and Human Services has launched an effort to streamline clinical research, and legislation is ...
Illinois agreed to a federal court order issued late last week that will temporarily shield some medical professionals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results